(a) In addition to the authority granted to a pharmacist under § 12-508 of this subtitle, a pharmacist, in accordance with regulations adopted by the Board, may administer:
(1) A self-administered drug to a patient that is prescribed by an authorized prescriber; and
(2) Subject to subsection (b) of this section, a maintenance injectable medication or an injectable medication for treatment of a sexually transmitted infection that is not a biological product to a patient:
(i) That is prescribed by an authorized prescriber;
(ii) In accordance with a standing order issued by an authorized public health official; or
(iii) In accordance with a protocol under Subtitle 6A of this title.
Written approval
(b) A pharmacist may not administer an initial dose of a maintenance injectable medication product or an injectable medication for treatment of a sexually transmitted infection under subsection (a)(2) of this section unless the pharmacist receives written approval from the prescriber.
Regulations
(c)(1) On or before September 1, 2021, the Board, in consultation with the State Board of Physicians and the State Board of Nursing, shall adopt regulations establishing standard procedures:
(i) For notifying a patient about payment for services before the pharmacist administers a maintenance injectable medication or an injectable medication for treatment of a sexually transmitted infection;
(ii) That a pharmacist must use to administer:
1. A maintenance injectable medication after an initial dose is administered by the prescriber; or
2. An injectable medication for treatment of a sexually transmitted infection;
(iii) That a pharmacist must use to administer an initial dose of a maintenance injectable medication or an injectable medication for treatment of a sexually transmitted infection if the administration of the initial dose is authorized under subsection (b) of this section; and
(iv) For communicating to the prescriber whether a medication was administered to a specific patient and relevant information about the patient's condition.
(2) The regulations shall require a pharmacist to:
(i) Except as provided in paragraph (3) of this subsection, complete a training program approved by the Board for:
1. Administering maintenance injectable medications and injectable medications for treatment of a sexually transmitted infection; and
2. Managing the populations the pharmacist serves, the medications being administered, and the current guidelines relating to these populations and medications;
(ii) Follow the standard procedures established by the Board; and
(iii) After administering a maintenance injectable medication or an injectable medication for treatment of a sexually transmitted infection:
1. Notify the prescriber that the maintenance injectable medication or injectable medication for treatment of a sexually transmitted infection was administered and of any relevant details about the patient's condition;
2. Provide the patient with a written record of the maintenance injectable medication or injectable medication for treatment of a sexually transmitted infection administered;
3. Record in any electronic or written health record on the patient maintained by the pharmacist:
A. The administering of the maintenance injectable medication or injectable medication for treatment of a sexually transmitted infection; and
B. Any pertinent details about the patient's condition; and
4. Notify the patient of the need to attend any upcoming appointments the patient has scheduled with the prescriber.
(3) The regulations shall waive the requirement to complete a training program for a pharmacist who already has undergone the training as part of the pharmacist's formal educational program.
Credits
Added by Acts 2015, c. 447, § 1, eff. Oct. 1, 2015. Amended by Acts 2021, c. 757, § 1, eff. May 30, 2021; Acts 2021, c. 758, § 1, eff. May 30, 2021; Acts 2022, c. 719, § 1, eff. Oct. 1, 2022; Acts 2022, c. 720, § 1, eff. Oct. 1, 2022.
MD Code, Health Occupations, § 12-509, MD HEALTH OCCUP § 12-509
Current through legislation effective through April 9, 2023, from the 2024 Regular Session of the General Assembly. Some statute sections may be more current, see credits for details.
